Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13036979 | 1.00 | BCHE (0.41) | BCHEKDM4EPOLBPKMTSHR | |
| SCHEMBL16508743 | 0.89 | SMN1; SMN2 (0.43) | BCHEKDM4EPOLBPKMTSHR | |
| SCHEMBL5773887 | 0.84 | KDM4E (0.39) | BCHEKDM4ESMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL13036980 | 0.84 | KDM4E (0.39) | BCHEKDM4ESMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL27597209 | 0.84 | CYP2D6 (0.43) | BCHEKDM4EPOLBPKMTSHR | |
| SCHEMBL13036983 | 0.83 | L3MBTL1 (0.53) | BCHESMN1; SMN2L3MBTL1ALDH1A1LMNA | |
| SCHEMBL16905075 | 0.80 | KDM4E (0.42) | KDM4EPOLBTSHRSIGMAR1L3MBTL1 | |
| SCHEMBL13036981 | 0.79 | KDM4E (0.44) | BCHEKDM4ESMN1; SMN2ALDH1A1ACHE | |
| SCHEMBL26433884 | 0.79 | L3MBTL1 (0.52) | KDM4EPOLBSMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL15014507 | 0.79 | L3MBTL1 (0.52) | KDM4EPOLBSMN1; SMN2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | BCHE 2929/4885KDM4E 2333/4885POLB 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.